Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Molecular Chaperone
CytRx Reports Second Quarter Financial Results
August 27th, 2007
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, reported financial results for the three and six months ended June 30, 2007. "We are aggressively executing on our strategy to broaden research and development activities related to our novel, orally-administered molecular chaperone amplification technology, and have announced plans for clinical testing in three important indications representing large market opportunities," said Steven A. Kriegsman, President and CEO. "We continue on track to begin our planned Phase IIb clinical trial with our lead molecular chaperone drug candidate...
Source: Clinical Trials Week (2007-08-27)
|
